A study led by researchers at Tsinghua University in Beijing has elicited the mechanism whereby the protein leucine-rich repeat kinase 2 prevents alveolar type II epithelial cell dysfunction, limiting profibrotic responses during progression of pulmonary fibrosis.
Shares of Bellerophon Therapeutics Inc. (NASDAQ:BLPH), rescued from potential delisting by a recent reverse stock split, shot 168.4% higher to $9.20 on Feb. 18 as new top-line data from a small phase II study showed its inhaled nitric oxide delivery system, Inopulse, delivered significant improvements in blood flow for people with pulmonary hypertension (PH) associated with pulmonary fibrosis (PF).
